Physician profile
Seth Avner
NPI 1699151282
$4,219.78
in general payments reported to CMS, 2019-2025
29 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $614 · 2020: $125 · 2021: $178 · 2022: $194 · 2023: $909 · 2024: $1,115 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,010 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,009.85 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $474.98 | 2025 | Rapiblyk |
| Novartis Pharmaceuticals Corporation | $451.66 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $380.81 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $342.89 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $266.53 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $204.13 | 2019-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $199.03 | 2021-2025 | Camzyos |
| Abiomed | $195.37 | 2024-2025 | Impella |
| Merck Sharp & Dohme LLC | $186.84 | 2022-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $164.48 | 2023-2025 | |
| Heartflow, INC. | $151.48 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $143.97 | 2024 | Opsumit, Uptravi |
| Baxter Healthcare | $119.81 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Cvrx, INC. | $119.68 | 2022-2024 | Barostim Neo System |
| Vifor Pharma, INC. | $115.83 | 2023 | Veltassa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $115.24 | 2019 | |
| Medtronic Vascular, INC. | $102.00 | 2019 | |
| Pfizer INC. | $91.24 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $63.29 | 2024-2025 | Amvuttra, Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.75 | 2024-2025 | Jardiance |
| Esperion Therapeutics, INC. | $57.20 | 2023-2025 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $45.77 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $39.92 | 2024 | Zio Monitor, Zio Xt Patch |
| Amgen INC. | $37.54 | 2025 | Repatha |
| Philips North America LLC | $25.47 | 2023 | |
| Lilly USA, LLC | $16.30 | 2023 | Mounjaro |
| Bridgebio Pharma, INC. | $15.70 | 2025 | Attruby |
| Regeneron Healthcare Solutions, INC. | $15.46 | 2025 | Evkeeza |
| Kiniksa Pharmaceuticals, LTD. | $14.41 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Avner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.